Posted: 23rd June 2022
A pharmacology company set up at the University of Birmingham’s Research Park is continuing its growth trajectory by taking up residency at PHTA – the University’s forthcoming flagship facility dedicated to translational health research.
Founded in 2017, Gifford Bioscience is a preclinical contract research organisation (CRO) which provides services in radioligand binding assays, receptor affinity occupancy studies, autoradiography and SPR (Biacore). The company undertakes standard or custom assays on customer samples to precise specification, and its additional capabilities include assay design, cell culture, and in-house production of membrane preparations.
Since its inception, Gifford Bioscience has been based at The BioHub Birmingham – a fully serviced biomedical incubator designed to accommodate life science companies from proof-of-concept through to expansion.
With Birmingham Health Innovation Campus currently under construction and No1 BHIC – including PHTA – set to open at the end of 2023, Gifford Bioscience is seizing the opportunity to expand its rapidly growing team of researchers and scientists, taking mixed laboratory and office space.
Managing Director Macer Gifford commented: “We chose Birmingham over the Golden Triangle destinations in 2017, and we’re now sure we made the right choice. We recruit top-notch PhDs from the Universities, while having access to resources such as the Human Biomaterials Resource Centre and Queen Elizabeth Hospital gives us deep capabilities in the assays we offer. And then there is the quality of the laboratory space itself. Being part of the life sciences ecosystem here is a real competitive advantage for us, and having the opportunity to expand to a brand new facility which is part of that same collaborative community is exactly what we need.”
PHTA’s CEO, Professor Gino Martini, added: “We are delighted to welcome a true Birmingham success story to PHTA. Our aspiration has always been to provide innovative life sciences with much-needed grow-on space, and being able to give Gifford Bioscience the greater capacity it requires is a really positive development for PHTA and BHIC. Our space has been designed to maximise the opportunities for innovators to interact, creating opportunities to share experience and best practice, and so we’re excited to see the outcomes of collaborations with companies like Gifford when we open.”
PHTA is currently based at the Institute of Translational Medicine and can facilitate collaborations with clinical-academic experts from across the Birmingham Health Partners ecosystem before we move to No1 BHIC. To discuss capabilities and capacity, contact a member of the team.
Visit the Gifford Bioscience website for further details on their specialist services.